Most Read Articles
one year ago
Cannabinoid hyperemesis syndrome (CHS) should be regarded as an important differential diagnosis in recurrent nausea and vomiting, according to a retrospective cohort study .
Jackey Suen, one year ago
Several biomarker candidates may improve screening and monitoring of treatment response in colorectal cancer (CRC), inflammatory bowel disease (IBD) and hepatocellular carcinoma (HCC), say experts of the Department of Medicine and Therapeutics, Chinese University of Hong Kong (CUHK), at the CUHK’s Advances in Medicine 2015 conference.
one year ago
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.
one year ago
In an exclusive interview with MIMS Doctor, renowned gastroenterologists from Subang Jaya Medical Centre, Dr Tan Soon Seng and Dr Ranjeev C K Prabhakeran,
shared their perspectives and experiences on the use of Fuse® (Full Spectrum Endoscopy) in their clinical practice. Both of them have been practicing gastroenterology
for almost 20 years and have completed more than 1,200 procedures using the Fuse® system.

Fuse® has been available in Malaysia since January 2015. Subang Jaya Medical Centre is the first medical centre in Asia and the ONLY one in Malaysia to use the
Fuse® at the present moment. As cited in The Lancet Oncology,1 March 2014, Fuse® Endoscopy System detected 69% more pre-cancerous polyps than standard forwardviewing colonoscopy.

Wait time, PCP status tied to GI clinic nonattendance

10 days ago
How to increase patient visits and keep them

The factors associated with missed appointments at a gastroenterology (GI) clinic are wait time, ethnicity, marital status and primary care provider (PCP) status, a recent study has found.

A case-control study was performed using data from the electronic health record of patients scheduled for an appointment at the adult GI clinic at the Banner University Medical Center between March and October 2014. Those who missed their appointment during the study period served as cases.

Researchers randomly selected controls from patients who completed their appointment during the study period. Univariate and multivariate logistic regression analyses were conducted.

There were 2,331 scheduled clinic appointments during the study period, of which 195 (8.4 percent) were missed appointments.

There was a significant association between longer waiting time from referral to schedule appointment and missed appointment (adjusted odds ratio [AOR], 1.014; 95 percent CI, 1.01 to 1.02; p<0.001). Patients without PCPs were more likely to miss their appointment than those with PCPs (AOR, 0.35; 0.18 to 0.66; p=0.001).

Among patient demographic characteristics, missed appointment was associated with marital status and ethnicity.

In a previous study that estimated the prevalence of nonattendance at scheduled appointments for outpatients seeking primary care, researchers found that nonattendance was significantly associated with age, number of issues in the personal health record, history of nonattendance, appointment scheduled later than 4pm, specific days of the week, and time between the request for and date of appointment. [Patient Prefer Adherence 2013;7:1163-1170]

Further studies are warranted to evaluate the effects of intervention strategies directed at reducing appointment wait time and increasing PCP-based care, according to researchers of the current study, adding that missed clinic appointments “reduce clinic efficiency, waste resources and increase costs.”

Editor's Recommendations
Most Read Articles
one year ago
Cannabinoid hyperemesis syndrome (CHS) should be regarded as an important differential diagnosis in recurrent nausea and vomiting, according to a retrospective cohort study .
Jackey Suen, one year ago
Several biomarker candidates may improve screening and monitoring of treatment response in colorectal cancer (CRC), inflammatory bowel disease (IBD) and hepatocellular carcinoma (HCC), say experts of the Department of Medicine and Therapeutics, Chinese University of Hong Kong (CUHK), at the CUHK’s Advances in Medicine 2015 conference.
one year ago
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.
one year ago
In an exclusive interview with MIMS Doctor, renowned gastroenterologists from Subang Jaya Medical Centre, Dr Tan Soon Seng and Dr Ranjeev C K Prabhakeran,
shared their perspectives and experiences on the use of Fuse® (Full Spectrum Endoscopy) in their clinical practice. Both of them have been practicing gastroenterology
for almost 20 years and have completed more than 1,200 procedures using the Fuse® system.

Fuse® has been available in Malaysia since January 2015. Subang Jaya Medical Centre is the first medical centre in Asia and the ONLY one in Malaysia to use the
Fuse® at the present moment. As cited in The Lancet Oncology,1 March 2014, Fuse® Endoscopy System detected 69% more pre-cancerous polyps than standard forwardviewing colonoscopy.